Top Story Today
Apogee Scored $1.3 Billion From Blackstone Without Giving Up a Single Share
A biotech founded in 2022 just locked down $1.3 billion from Blackstone in a deal that barely touches its equity. The structure: up to $800 million in synthetic royalties (Blackstone gets a cut of future sales that shrinks as revenue grows and vanishes entirely once cumulative product revenue exceeds $8 billion) plus $500 million in optional senior debt. The cash arrives in tranches tied to clinical milestones, funding Apogee's eczema drug zumilokibart through Phase 3 and into commercialization. The drug's pitch? Turning 26 annual injections into as few as two, backed by Phase 2 data showing a 71% reduction in eczema severity.
Why it matters: Synthetic royalty financings have quadrupled in cumulative value over five years, and Apogee's deal towers over the typical transaction. If this structure keeps working for pre-approval biotechs, it could reshape how the entire industry funds late-stage development without crushing shareholders.
Read more →Clinical and Regulatory
AstraZeneca's Breast Cancer Drug Got a 6-3 No. The FDA Isn't Ready to Agree.
An FDA advisory panel voted 6-3 against camizestrant, AstraZeneca's oral breast cancer drug, not because it doubted the drug works, but because the trial relied on blood-based mutation testing to trigger treatment switches before scans showed progression. The FDA extended its decision deadline to review additional data coming at ASCO 2026. The outcome could set (or stall) the precedent for liquid biopsy-guided cancer treatment.
Read more →The Sidekick That Could Rescue KRAS Inhibitors After They Fail
Kura Oncology is presenting early clinical data at ASCO 2026 on darlifarnib, a companion drug designed to block the escape route tumors use when KRAS inhibitors stop working. In preclinical models, adding darlifarnib to resistant tumors triggered regressions where switching KRAS drugs alone did nothing. If the human data hold up, it could become the universal sidekick for a drug class projected to hit $7.85 billion by 2034.
Read more →The FDA Finally Killed the 19-Day Lockout on Acne Prescriptions
After 21 years of complaints, the FDA gutted iPLEDGE's most punishing rules. Starting August 8, patients who miss their isotretinoin pickup window can retest immediately instead of waiting 19 days. Home pregnancy tests replace mandatory lab visits for ongoing treatment. For roughly a million Americans on the drug each year, refills just got dramatically less painful.
Read more →Deals and M&A
The Endoscope Giant Just Spent $270M to Stop Watching Cancer and Start Treating It
Olympus, which controls a commanding share of the GI endoscope market, is acquiring Israeli startup BioProtect for $270 million in cash. BioProtect makes a biodegradable balloon that shields healthy tissue during prostate cancer radiation. At 18.6x trailing revenue it's a steep price, but with 1.5 million new prostate cancer cases annually and pipeline ambitions across multiple tumor types, Olympus is betting on a platform, not a single product.
Read more →Congress Wants to Cut Off Pharma's Favorite New Shopping Aisle
Chinese biotechs signed 186 out-licensing deals worth $137.7 billion in 2025, roughly 10x the level from 2021. Now lawmakers are pushing to add biotech to the COINS Act, which screens U.S. investments flowing to China. Treasury has until March 2027 to finalize rules. Even a notification regime (rather than an outright ban) could chill dealmaking by adding months of uncertainty to every cross-border negotiation.
Read more →Funding and IPOs
The Team Behind a $13 Billion Exit Just Filed for Round Two
Kardigan, founded by the crew that sold MyoKardia to BMS for $13.1 billion, just filed for a Nasdaq IPO under ticker KARD. They're bringing three late-stage heart drugs, $554 million in private backing from investors including ARCH, Perceptive Advisors, Sequoia Heritage, and Fidelity, and a contrarian thesis: cardiovascular disease can compete for investor dollars in a market obsessed with oncology and AI. It's shaping up as a litmus test for cardiac biotech's IPO appetite.
Read more →